Blockchain Registration Transaction Record

Tonix Pharmaceuticals Expands TONMYA Access to 52M Commercial Lives

Tonix Pharmaceuticals expands TONMYA access to 52 million U.S. commercial lives via new coverage agreement. Learn about the fibromyalgia treatment and its impact.

This expansion means millions of fibromyalgia patients now have access to a new, non-opioid treatment option, potentially reducing opioid dependency and improving pain management. The coverage agreement with a second major group purchasing organization signals growing insurer confidence in TONMYA, which could pave the way for broader adoption and further research into its use for other conditions like depression and stress disorders.